# NEA Management Company, LLC: Form 13F holdings

An institutional investment manager in TIMONIUM, MD. SEC CIK 1512848.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $1.59bn
- Positions: 26 (26 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1512848/000107261326000684/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Trevi Therapeutics, Inc. (TRVI)](/companies/trvi.md) | COM | $246.6m | 15.5% | 13,222,228 |  | Unchanged |
| [MBX Biosciences, Inc. (MBX)](/companies/mbx.md) | COM | $199.5m | 12.6% | 3,614,486 |  | Unchanged |
| [Monte Rosa Therapeutics, Inc. (GLUE)](/companies/glue.md) | COM | $186.2m | 11.7% | 7,692,298 |  | Unchanged |
| [Celcuity Inc. (CELC)](/companies/celc.md) | COM | $179.0m | 11.3% | 1,710,561 |  | Reduced −575,000 |
| [Spyglass Pharma, Inc. (SGP)](/companies/sgp.md) | COM SHS | $164.6m | 10.4% | 7,392,301 |  | Unchanged |
| [Savara, Inc. (SVRA)](/companies/svra.md) | COM | $150.7m | 9.5% | 24,471,264 |  | Unchanged |
| [Zenas BioPharma, Inc. (ZBIO)](/companies/zbio.md) | COM | $102.1m | 6.4% | 4,023,219 |  | Unchanged |
| [Coursera, Inc. (COUR)](/companies/cour.md) | COM | $72.6m | 4.6% | 12,867,769 |  | Unchanged |
| [Aurinia Pharmaceuticals, Inc. (AUPH)](/companies/auph.md) | COM | $67.4m | 4.2% | 3,969,834 |  | Unchanged |
| CRISPR Therapeutics AG | NAMEN AKT | $57.7m | 3.6% | 1,058,570 |  | Unchanged |
| [ORIC Pharmaceuticals, Inc. (ORIC)](/companies/oric.md) | COM | $44.6m | 2.8% | 4,118,621 |  | Unchanged |
| [Phathom Pharmaceuticals, Inc. (PHAT)](/companies/phat.md) | COM | $21.3m | 1.3% | 1,960,169 |  | Unchanged |
| [Korro Bio, Inc. (KRRO)](/companies/krro.md) | COM | $17.1m | 1.1% | 1,297,893 |  | Unchanged |
| X4 Pharmaceuticals, Inc. | COM | $15.1m | 1.0% | 3,233,743 |  | Unchanged |
| [Champions Oncology, Inc. (CSBR)](/companies/csbr.md) | COM NEW | $10.6m | 0.7% | 1,713,720 |  | Unchanged |
| [Nkarta, Inc. (NKTX)](/companies/nktx.md) | COM | $10.1m | 0.6% | 3,568,781 |  | Unchanged |
| [CVRx, Inc. (CVRX)](/companies/cvrx.md) | COM | $10.0m | 0.6% | 1,954,440 |  | Reduced −71,643 |
| [Black Diamond Therapeutics, Inc. (BDTX)](/companies/bdtx.md) | COM | $8.2m | 0.5% | 4,448,757 |  | Unchanged |
| [Karyopharm Therapeutics Inc. (KPTI)](/companies/kpti.md) | COM NEW | $5.6m | 0.4% | 576,780 |  | New +576,780 |
| [Inventiva SA (IVA)](/companies/iva.md) | ADS | $5.5m | 0.3% | 1,462,586 |  | Unchanged |
| [LeonaBio, Inc. (LONA)](/companies/lona.md) | COM | $4.3m | 0.3% | 464,398 |  | Unchanged |
| Senti Biosciences, Inc. | COM NEW | $4.2m | 0.3% | 3,775,615 |  | Unchanged |
| [Marker Therapeutics, Inc. (MRKR)](/companies/mrkr.md) | COM NEW | $2.4m | 0.2% | 1,625,678 |  | Unchanged |
| [OnKure Therapeutics, Inc. (OKUR)](/companies/okur.md) | COM CL A | $2.2m | 0.1% | 478,548 |  | Unchanged |
| [ImageneBio, Inc. (IMA)](/companies/ima.md) | COM | $295.0k | <0.1% | 50,005 |  | Unchanged |
| Gossamer Bio, Inc. | COM | $164.6k | <0.1% | 1,000,000 |  | Unchanged |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| Arcellx, Inc. | COMMON STOCK | $0 | 0.0% | 0 |  | Sold out −3,045,262 |

Source: SEC EDGAR, Form 13F-HR, accession 0001072613-26-000684. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.